Table 1

 Patient demographics and clinical characteristics at baseline*

Conventional DMARDs (n = 145)8 mg/kg Tocilizumab (n = 157)
*Except where indicated otherwise, values are the mean ± SD.
†RA functional status determined by American College of Rheumatology criteria. RA stage determined by Steinbrocker’s criteria.
DMARDs, disease-modifying antirheumatic drugs; Tocilizumab, humanised anti-interleukin-6 receptor antibody; RA, rheumatoid arthritis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; TSS, total Sharp score; MTX, methotrexate.
    Age, years53.1±12.552.9±11.6
    Male:female ratio26:11932:125
Clinical characteristics
    RA duration, years2.4±1.32.2±1.4
    No. of failed DMARDs, mean (range)2.8 (1–7)2.7 (1–7)
    Functional Class†, I:II:III:IV11:114:20:012:126:19:0
    RA Stage†, I:II:III:IV18:57:51:1914:77:46:20
    Tender joint count, 0–49 scale14.4±7.215.3±7.3
    Swollen joint count, 0–46 scale11.9±5.512.5±6.4
    ESR, mm/h71.0±25.270.8±27.9
    CRP, mg/L49±2947±29
Radiographic findings
    Modified TSS, 0–448 scale30.6±42.028.3±43.9
    Erosion score, 0–280 scale13.9±21.713.8±24.6
    Joint space narrowing score, 0–168 scale16.7±21.814.5±20.8
    Estimated annual TSS progression12.3±16.214.1±26.9
Treatment classification
    MTX and at least one DMARD, patients (%)53 (37)43 (27)
    MTX monotherapy, patients (%)44 (30)73 (46)
    DMARDs/immunosuppressants, patients (%)32 (22)30 (19)
MTX dose, mg/week7.1±1.96.9±2.0
Prednisolone equivalent corticosteroid dose, mg/day5.4±3.25.4±3.1